Clinical Trials Logo

Filter by:
  • Not yet recruiting  
  • Page [1] ·  Next »
NCT ID: NCT03429582 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Development of Thermoablation Device

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this academic-industrial partnership will be to compare two thermoablation modalities using devices adapted to low and middle income countries (LMICs) to traditional CO2-based cryotherapy for the treatment of cervical precancer. The investigators will investigate whether the cure rates of cervical intraepithelial neoplasia 2 and more severe diagnoses (CIN2+) with these devices are non-inferior compared to that of conventional cryotherapy. The results of this study will affect other research areas by serving as a springboard to exploring treatment alternatives that are amenable to low-resource settings and thus will reach the most vulnerable populations.

NCT ID: NCT03417037 Not yet recruiting - Lung Cancer Clinical Trials

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Start date: February 24, 2018
Phase: Phase 3
Study type: Interventional

This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.

NCT ID: NCT03416127 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Diabetes Mellitus Type 2

Start date: March 1, 2018
Phase: Phase 2
Study type: Interventional

Glycemic control is naturally the principal topic of diabetes and complications that can be developed as a consequence of loss of sensitivity to perceive insulin signals by the cell. The glycemic control goals established by the ADA are: glycosylated hemoglobin (A1C) <7.0%, fasting plasma glucose 80-130 mg/dL and casual plasma glycemia <180 mg/dL. The first-line treatment in patients of recent diagnosis is metformin, however, studies have shown that propolis, a resinous balsamic material collected by the Apis mellifera bee, from sprouts, exudates of trees and other parts of the plants, represents a very important and promising natural alternative in medicine, which can be considered as an antidiabetic agent. The aim of this study is to evaluate the effect of propolis or metformin administration on glycemic control in patients with type 2 Diabetes Mellitus without pharmacological treatment. The investigators hypothesis is that propolis or metformin administration, modify the glycemic control in patients with type 2 Diabetes Mellitus without pharmacological treatment.

NCT ID: NCT03390504 Not yet recruiting - Urothelial Cancer Clinical Trials

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Start date: January 31, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after one prior treatment.

NCT ID: NCT03379675 Not yet recruiting - Clinical trials for Respiratory Syncytial Virus Infections

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Start date: January 31, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the antiviral effect of JNJ-53718678 at 2 dose levels (80 milligrams [mg] and 500 mg) once daily for 7 days in adults with Respiratory Syncytial Virus (RSV) infection, as measured by RSV viral load in nasal secretions by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay.

NCT ID: NCT03377374 Not yet recruiting - Pharyngitis Clinical Trials

L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis

Start date: December 28, 2017
Phase: N/A
Study type: Interventional

RCT in children (6m to 5y) with pharyngitis and/or tonsillitis who will be allocated to receive for 10 days L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289) at a dose of 2x10^8 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) or placebo drops, as treatment for clinical condition. Duration of symptoms and reduction of pain (odynophagia) severity during treatment will be measured as primary outcome

NCT ID: NCT03375125 Not yet recruiting - Clinical trials for Periodontitis and Pregnancy

L. Reuteri ATCC PTA 5289 + L. Reuteri DSM 17938 in Pregnant Women

Start date: December 20, 2017
Phase: N/A
Study type: Interventional

Randomized controlled tril to evaluate the safety and efficacy for the combination of L. reuteri ATCC PTA 5289 & L. reuteri DSM 17938 in pregnant women with periodontitis and/or gingivits to improve oral health and at the same time reduce the risk for prematurity or intrauterine growth retardation (IUGR). Women in this study wil receive L. reuteri Prodentis (L. reuteri DSM 17938 & L. reuteri ATCC PTA 5289 ) at a dose of 2x10^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day since randomization until delivery. The control group will receive placebo lozenges which contains identical ingredients except for lacking the bacteria. One lozenges is to be taken twice per day (one in the morning and one in the afternoon. The study product will be kept refrigerated (+20 - +80 C)

NCT ID: NCT03362697 Not yet recruiting - Clinical trials for Urinary Tract Infection in Pregnancy

Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women

UTIPregnant
Start date: December 15, 2017
Phase: N/A
Study type: Interventional

Prevalence of uro-genital infections during pregnancy move between 7% to 12% in developed countries, meanwhile in developing countries this figure moved between 14% and until 55%, such is the case of Mexico. Meanwhile use of antibiotics for 3 to 7 days had established as a standard of care, the use of non-antibiotic therapy, such as cranberry powder or probiotics for prevention/treatment of this conditions is scarce. Randomized controlled trial aimed to evaluate the safety and efficacy of probiotic vs. antibiotics to treat pregnant women with uncomplicated cystitis or asymptomatic bacteriuria

NCT ID: NCT03334435 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

BREEZE-AD3
Start date: March 6, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.

NCT ID: NCT03330938 Not yet recruiting - Clinical trials for End-Stage Renal Disease

Decreasing Depression and Anxiety and Their Effect on QoL of ESRD Patients (End-Stage Renal Disease)

ESRD
Start date: December 1, 2017
Phase: N/A
Study type: Interventional

This study evaluates the effect of a single cognitive-behavioral intervention (CBI) in a control group against the same CBI plus the strengthening of resiliency skills in an experimental group, on ESRD patients.